Faron Pharmaceuticals Oy (AIM:FARN)
London · Delayed Price · Currency is GBP · Price in GBX 39.60
-1.40 (-3.41%)
Aug 14, 2026, 4:35 PM GMT
Faron Pharmaceuticals Oy Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.32 | 9.5 | 6.88 | 6.99 | 6.85 |
Cash & Short-Term Investments | 12.32 | 9.5 | 6.88 | 6.99 | 6.85 |
Cash Growth | 29.61% | 38.22% | -1.65% | 2.00% | 66.82% |
Other Receivables | 0.51 | 0.28 | 0.23 | 0.91 | 1.42 |
Receivables | 0.51 | 0.28 | 0.23 | 0.91 | 1.42 |
Prepaid Expenses | 3 | 1.28 | 1.76 | 1.84 | 3.75 |
Other Current Assets | - | -0 | 0 | - | - |
Total Current Assets | 15.83 | 11.07 | 8.87 | 9.73 | 12.02 |
Property, Plant & Equipment | 0.19 | 0.3 | 0.2 | 0.33 | 0.21 |
Other Intangible Assets | 1.12 | 1.11 | 1.09 | 1.15 | 0.9 |
Other Long-Term Assets | 0.04 | 0.05 | 0.06 | 0.06 | 0.05 |
Total Assets | 17.17 | 12.52 | 10.22 | 11.27 | 13.18 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.82 | 3.7 | 8.97 | 6.01 | 2.23 |
Accrued Expenses | 3.45 | 2.63 | 2.4 | 2.45 | 4.06 |
Current Portion of Long-Term Debt | 10.27 | 3.72 | 3.48 | 1.85 | 0.43 |
Current Portion of Leases | 0.13 | 0.12 | 0.16 | 0.15 | 0.18 |
Other Current Liabilities | 1.21 | - | - | - | 0.28 |
Total Current Liabilities | 18.87 | 10.17 | 15.01 | 10.47 | 7.18 |
Long-Term Debt | 14.2 | 8.09 | 9.42 | 11.1 | 2.92 |
Long-Term Leases | 0.08 | 0.19 | 0.05 | 0.16 | 0.02 |
Other Long-Term Liabilities | 2.53 | 3.84 | 0.9 | 1.01 | 0.15 |
Total Liabilities | 35.68 | 22.28 | 25.38 | 22.75 | 10.26 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.69 | 2.69 | 2.69 | 2.69 | 2.69 |
Retained Earnings | -222.86 | -197.42 | -172.21 | -143.71 | -116.27 |
Comprehensive Income & Other | 201.66 | 184.97 | 154.36 | 129.55 | 116.49 |
Shareholders' Equity | -18.51 | -9.76 | -15.16 | -11.48 | 2.92 |
Total Liabilities & Equity | 17.17 | 12.52 | 10.22 | 11.27 | 13.18 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 24.68 | 12.11 | 13.11 | 13.27 | 3.55 |
Net Cash (Debt) | -12.36 | -2.61 | -6.24 | -6.28 | 3.31 |
Net Cash Growth | - | - | - | - | 274.41% |
Net Cash Per Share | -0.11 | -0.03 | -0.10 | -0.11 | 0.07 |
Filing Date Shares Outstanding | 114.42 | 104.62 | 68.79 | 59.81 | 53.23 |
Total Common Shares Outstanding | 114.42 | 104.62 | 68.79 | 59.81 | 53.23 |
Working Capital | -3.05 | 0.89 | -6.14 | -0.74 | 4.85 |
Book Value Per Share | -0.16 | -0.09 | -0.22 | -0.19 | 0.05 |
Tangible Book Value | -19.62 | -10.87 | -16.25 | -12.63 | 2.02 |
Tangible Book Value Per Share | -0.17 | -0.10 | -0.24 | -0.21 | 0.04 |
Machinery | 0.03 | 0.03 | 0.03 | 0.06 | 0.06 |